Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin.
作者信息
Million Matthieu, Giraud-Gatineau Audrey, Lagier Jean-Christophe, Parola Philippe, Gautret Philippe, Raoult Didier
机构信息
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France; Assistance Publique- Hôpitaux de Marseille (AP-HM), Marseille, France; Centre D'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille, France.
出版信息
Travel Med Infect Dis. 2021 Jan-Feb;39:101954. doi: 10.1016/j.tmaid.2020.101954. Epub 2020 Dec 13.
Abstract
摘要
相似文献
1
Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin.对勒博 D 和雷韦斯特 M 的回复：没有证据表明用羟氯喹和阿奇霉素对 COVID-19 患者进行早期治疗有临床益处。
Travel Med Infect Dis. 2021 Jan-Feb;39:101954. doi: 10.1016/j.tmaid.2020.101954. Epub 2020 Dec 13.
2
Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".关于羟氯喹和阿奇霉素作为新冠病毒病早期治疗药物疗效的相互矛盾的证据。对“法国马赛1061例新冠病毒病患者早期使用羟氯喹和阿奇霉素治疗的回顾性分析”的评论
Travel Med Infect Dis. 2020 Sep-Oct;37:101861. doi: 10.1016/j.tmaid.2020.101861. Epub 2020 Sep 1.
3
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.羟氯喹、阿奇霉素和环索奈德三联疗法治疗 COVID-19 肺炎。
J Microbiol Immunol Infect. 2021 Feb;54(1):109-112. doi: 10.1016/j.jmii.2020.09.003. Epub 2020 Oct 5.
4
Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒清除的影响：对埃尔韦·塞利格曼的回应
Int J Antimicrob Agents. 2021 Mar;57(3):106306. doi: 10.1016/j.ijantimicag.2021.106306. Epub 2021 Feb 14.
5
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".没有证据表明用羟氯喹和阿奇霉素对新冠病毒疾病患者进行早期治疗有临床益处：对《用羟氯喹和阿奇霉素对新冠病毒疾病患者进行早期治疗：法国马赛1061例回顾性分析》的评论
Travel Med Infect Dis. 2020 Jul-Aug;36:101819. doi: 10.1016/j.tmaid.2020.101819. Epub 2020 Jul 3.
6
Hydroxychloroquine + azithromycin treatment in elderly patients.老年患者的羟氯喹啉 + 阿奇霉素治疗
Int J Antimicrob Agents. 2021 Apr;57(4):106313. doi: 10.1016/j.ijantimicag.2021.106313. Epub 2021 Mar 11.
7
Has the door closed on hydroxychloroquine for SARS-COV-2?羟氯喹啉治疗新冠病毒（SARS-CoV-2）的大门是否已关闭？
Clin Microbiol Infect. 2021 Jan;27(1):3-5. doi: 10.1016/j.cmi.2020.10.011. Epub 2020 Oct 20.
8
Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment.对新冠病毒（COVID-19）羟氯喹治疗候选药物的初步数据进行平衡评估。
Int J Antimicrob Agents. 2021 Mar;57(3):106292. doi: 10.1016/j.ijantimicag.2021.106292.
9
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients.羟氯喹和阿奇霉素早期联合治疗可降低 10429 例 COVID-19 门诊患者的死亡率。
Rev Cardiovasc Med. 2021 Sep 24;22(3):1063-1072. doi: 10.31083/j.rcm2203116.
10
Azithromycin, a questionable treatment for COVID-19.阿奇霉素，一种对新冠病毒病存疑的治疗方法。
Int J Antimicrob Agents. 2021 Mar;57(3):106280. doi: 10.1016/j.ijantimicag.2021.106280. Epub 2021 Jan 19.
引用本文的文献
1
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?用磷酸二酯酶 5 抑制剂和羟氯喹联合治疗糖尿病——预防 COVID-19 的可能策略？
Mol Cell Biochem. 2023 Mar;478(3):679-696. doi: 10.1007/s11010-022-04520-2. Epub 2022 Aug 29.
2
Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing.通过全基因组测序从患者粪便样本中检测严重急性呼吸综合征冠状病毒2（SARS-CoV-2）
Gut Pathog. 2021 Jan 30;13(1):7. doi: 10.1186/s13099-021-00398-5.
Zotero 插件